edwin
cohn
introduc
becom
wide
use
commerci
fraction
method
plasma
protein
involv
multipl
step
precipit
physic
separ
centrifug
filtrat
precipit
effluent
use
chang
ph
temperatur
ionic
strength
ethanol
concentr
gradient
occurr
differ
step
precipit
filtrat
fraction
process
protein
isol
later
schemat
gener
safer
infecti
agent
albumin
globulin
fraction
prove
extrem
safe
particularli
regard
transmiss
hepat
virus
hiv
howev
process
infal
deviat
proper
process
result
diseas
transmiss
import
plasma
protein
deriv
factor
viii
ix
separ
earli
fraction
process
reap
benefit
ad
layer
fraction
process
pasteur
use
effect
inactiv
virus
albumin
fraction
stabil
small
chain
fatti
acid
earli
protein
especi
clot
factor
denatur
pasteur
process
unless
addit
stabil
ad
termin
heat
inactiv
lyophil
clot
factor
brought
vari
result
depend
upon
temperatur
process
time
dri
heat
treatment
lyophil
clot
factor
prevent
transmiss
hbv
hcv
hiv
increas
dri
heat
temperatur
h
destroy
hiv
hbv
hcv
although
virus
especi
hav
human
parvo
may
complet
inactiv
ad
humid
vapor
heat
improv
viral
kill
heat
inactiv
littl
h
result
viral
inactiv
lipid
envelop
virus
process
appli
intraven
immunoglobulin
concentr
littl
protein
lost
exposur
low
ph
inactiv
mani
envelop
virus
howev
among
commerci
protein
immunoglobulin
stabl
necessari
acid
condit
ph
use
organ
solvent
deterg
process
coagul
factor
inactiv
virus
envelop
virus
solvent
deterg
combin
disrupt
lipid
envelop
prevent
viru
bind
cell
replic
incorpor
virucid
deterg
solvent
solvent
phosphat
deterg
h
process
plasma
pool
approxim
donor
produc
product
known
plasma
phosphat
remov
oil
extract
remov
chromatograph
adsorpt
plasma
protein
concentr
made
plasma
plasma
ffp
equival
licens
usa
europ
coagul
factor
technolog
inactiv
virus
treatment
also
result
loss
integr
plasma
protein
antiplasmin
protein
antiplasmin
crucial
maintain
haemostasi
especi
patient
liver
dysfunct
decreas
level
natur
anticoagul
protein
lead
hypercoagu
state
especi
massiv
plasma
transfus
use
massiv
trauma
therapeut
plasma
exchang
concern
along
econom
factor
result
remov
plasma
us
market
plasma
still
use
wide
europ
recent
two
new
treatment
procedur
develop
singl
unit
unit
plasma
yield
mean
recoveri
coagul
factor
anticoagul
includ
protein
proteas
inhibitor
includ
antiplasmin
total
protein
albumin
immunoglobulin
singl
unit
treatment
technolog
show
promis
potenti
overcom
drawback
origin
industri
treatment
process
nanofiltr
proven
effect
remov
wide
rang
virus
includ
virus
may
even
remov
virus
smaller
filter
pore
size
mani
current
licens
plasma
deriv
coagul
factor
immunoglobulin
subject
heat
pasteur
andor
treatment
also
nanofilt
class
plasma
protein
fraction
antithrombin
inhibitor
protein
c
fibrinogen
ceruloplasmin
nanofilt
without
appar
chang
protein
characterist
methylen
blue
mb
photoact
phenothiazin
dye
use
europ
year
singl
unit
plasma
mb
affin
nucleic
acid
surfac
virus
plasma
expos
ultraviolet
light
envelop
virus
easili
inactiv
howev
virus
resist
intracellular
virus
inactiv
mbultraviolet
light
freez
thaw
plasma
often
disrupt
cell
membran
leucocyt
thu
liber
viral
particl
leav
suscept
mb
residu
intact
white
blood
cell
contain
virus
remov
micropor
filter
neither
protozoa
bacteria
inactiv
mb
treatment
plasma
protein
moder
affect
fibrinogen
fviii
activ
reduc
mb
treatment
use
singl
unit
plasma
thu
elimin
risk
larg
plasma
pool
current
use
manufactur
plasma
macopharma
use
system
consist
membran
filter
mb
dye
illumin
bag
elimin
filter
storag
bag
membran
filter
remov
platelet
leucocyt
debri
plasma
pass
tube
contain
mb
pill
dissolv
plasma
flow
tube
illumin
bag
plasma
subject
illumin
sodium
lamp
emit
yellow
light
wavelength
nm
min
plasma
pass
mb
elimin
filter
remov
greater
residu
dye
photoderiv
million
mb
singl
unit
plasma
transfus
europ
without
unexpect
advers
outcom
psoralen
small
planar
molecul
cross
cell
membran
viral
capsid
intercal
base
nucleic
acid
upon
illumin
ultraviolet
nm
psoralen
react
dna
rna
pyrimidin
base
form
coval
bond
intranucl
internucl
acid
prevent
replic
transcript
rna
dna
psoralen
treatment
ultraviolet
light
result
reduct
broad
array
virus
bacteria
protozoa
level
unlik
transmit
infect
psoralen
synthet
psoralen
known
amotosalen
hydrochlorid
extens
test
platelet
plasma
amotosalen
photochem
treatment
demonstr
accept
safeti
profil
extens
toxicolog
studi
acut
toxic
repeat
dose
toxic
reproduct
toxic
phototox
mutagen
carcinogen
potenti
order
psoralen
platelet
concentr
must
volum
reduc
plasma
platelet
addit
solut
amotosalen
ad
platelet
incub
min
product
expos
ultraviolet
light
approxim
psoralen
photodegrad
remain
psoralen
remov
compound
absorpt
disc
intercept
amotosalen
system
evalu
three
clinic
trial
europ
eurosprit
involv
thrombocytopen
patient
two
trial
evalu
whole
platelet
one
assess
singl
donor
apheresi
platelet
studi
demonstr
equal
platelet
dose
transfus
intercept
convent
platelet
transfus
result
compar
platelet
count
increment
without
signific
differ
advers
reaction
usa
sprint
trial
evalu
haemostat
efficaci
safeti
thrombocytopen
oncolog
patient
receiv
intercept
singl
donor
apheresi
platelet
collect
amicu
separ
total
platelet
transfus
given
intercept
platelet
convent
platelet
incid
world
health
organ
grade
bleed
group
compar
incid
group
world
health
organ
grade
bleed
equival
patient
receiv
intercept
platelet
lower
platelet
count
increment
requir
platelet
transfus
shorter
interv
transfus
explan
differ
platelet
count
increment
pct
platelet
partli
explain
lower
mean
platelet
dose
disproportion
number
transfus
contain
platelet
dose
less
cell
transfus
reaction
fewer
pct
platelet
like
attribut
reduc
volum
plasma
pct
unit
well
increas
leucocyt
inactiv
result
less
cytokin
product
storag
howev
trend
toward
higher
frequenc
respiratori
complic
note
great
concern
us
food
drug
administr
appar
less
nation
regulatori
bodi
amotosalen
ultraviolet
light
use
plasma
system
much
like
use
platelet
coagul
studi
pct
plasma
demonstr
coagul
factor
rang
control
thaw
plasma
factor
viii
level
decreas
still
suffici
therapeut
use
signific
differ
quantiti
activ
von
willebrand
factor
pattern
distribut
von
willebrand
multim
activ
fibrinogen
maintain
function
activ
approxim
protein
c
well
antithrombin
maintain
activ
level
evid
coagul
factor
activ
result
treatment
factor
vii
kinet
pct
plasma
compar
standard
ffp
crossov
studi
studi
patient
congenit
coagul
factor
defici
coagul
factor
kinet
therapeut
efficaci
ffp
treat
amotosalen
ultraviolet
light
shown
consist
convent
ffp
random
control
trial
support
haemostasi
treatment
acquir
liver
diseas
liver
transplant
reveal
outcom
similar
convent
ffp
addit
studi
util
plasma
exchang
thrombot
thrombocytopenia
purpura
demonstr
similar
result
convent
plasma
cryoprecipit
also
produc
amotosalen
ultraviolet
plasma
preliminari
studi
indic
pct
cryoprecipit
coagul
factor
level
accept
riboflavin
vitamin
natur
occur
essenti
nutrient
use
agent
platelet
plasma
riboflavin
planar
structur
bind
nucleic
acid
intercal
dna
rna
base
upon
activ
riboflavin
ultraviolet
visibl
light
guanosin
base
oxid
result
singl
strand
break
nucleic
acid
damag
disrupt
nucleic
acid
incap
repair
replic
toxic
riboflavin
photoderiv
appear
caus
concern
riboflavin
breakdown
product
present
mani
food
natur
product
remov
spent
riboflavin
product
may
necessari
system
use
riboflavin
us
food
drug
administr
classifi
riboflavin
gener
regard
safe
compound
mirasol
prt
system
contain
ml
riboflavin
light
protect
pouch
illuminationstorag
bag
platelet
plasma
steril
connect
system
ml
plasma
platelet
product
transfer
bag
contain
riboflavin
dilut
final
concentr
product
subject
ultraviolet
illumin
riboflavinultraviolet
light
treatment
evalu
preclin
studi
found
result
reduct
infect
mani
pathogen
includ
west
nile
viru
intracellular
hiv
bacteria
protozoa
mirasol
system
demonstr
success
pathogen
reduct
select
platelet
unit
treatment
storag
day
viral
reduct
platelet
suffici
close
window
period
transmiss
hiv
chronic
phase
parvo
elimin
viraem
period
west
nile
viru
prevent
infect
due
staphylcoccu
epidermidi
escherichia
coli
result
log
reduct
leishmania
donovani
infantum
addit
plasma
unit
treat
riboflavinultraviolet
light
demonstr
log
reduct
parasit
studi
demonstr
signific
differ
control
treat
platelet
day
storag
regard
acceler
chang
platelet
morpholog
increas
platelet
activ
induc
partial
platelet
aggreg
riboflavinultraviolet
plasma
shown
retain
accept
level
clot
factor
without
evid
increas
compliment
activ
helinx
small
molecul
design
treatment
red
blood
cell
alkyl
agent
deriv
quinacrin
mustard
belong
class
frangibl
anchor
linker
effector
frale
compound
frale
compound
contain
intercal
group
insert
helic
region
dna
rna
effector
group
permit
coval
attach
nucleic
acid
central
frangibl
bond
orchestr
degrad
compound
posit
charg
planar
structur
easili
intercal
helic
region
neg
charg
nucleic
acid
process
depend
light
activ
frale
compound
activ
shift
lower
ph
storag
environ
higher
neutral
ph
red
blood
cell
caus
hydrolysi
gener
primari
degrad
product
dna
rna
ensu
rapidli
metabol
excret
leav
detect
parent
compound
remain
free
degrad
product
absorb
remov
compound
remov
step
bind
protein
cell
membran
well
nucleic
acid
potenti
remain
bound
surfac
contain
within
red
blood
cell
demonstr
wide
rang
virus
bacteria
protozoa
unexpect
toxic
describ
assay
red
blood
cell
storag
lesion
extracellular
potassium
leakag
haemoglobin
adenosin
diphosph
glucos
lactat
compar
control
red
blood
cell
red
blood
cell
function
appear
normal
vivo
surviv
studi
exceed
standard
h
two
random
control
trial
involv
patient
either
undergo
cardiovascular
surgeri
haemoglobinopathi
progress
antibodi
residu
red
blood
cell
bound
discov
two
subject
trial
suspend
consequ
find
addit
studi
reveal
patient
healthi
donor
never
expos
natur
occur
antibodi
react
treat
red
blood
cell
modif
made
treatment
process
reduc
amount
red
blood
cell
bound
attempt
elimin
immunoreact
immunogen
preliminari
find
indic
red
blood
cell
modifi
treatment
process
antibodi
form
exposur
origin
formul
well
antibodi
found
patient
donor
never
expos
antibodi
appear
impair
transfus
pose
clinic
problem
new
clinic
trial
initi
system
red
blood
cell
current
develop
found
success
mean
red
blood
cell
riboflavin
may
serv
one
materi
inactiv
pathogen
three
blood
compon
red
cell
platelet
plasma
current
leucoreduct
filter
effect
remov
virus
remov
total
prion
infect
endogenoussli
infect
blood
leucoreduct
filter
develop
remov
prion
exogen
endogen
infect
blood
effect
exogen
infect
studi
conduct
use
ml
red
blood
cell
ml
wtvol
high
titr
brain
homogen
hamster
infect
scrapi
final
homogen
concentr
endogen
infect
studi
util
red
blood
cell
process
ml
whole
blood
collect
hamster
new
prototyp
leucoreduct
prion
reduct
filter
effect
remov
log
scrapi
infect
exogen
infect
red
blood
cell
detect
prpsc
endogen
infect
hamster
endogen
infect
studi
red
blood
cell
transmit
diseas
six
anim
red
blood
cell
transmit
diseas
anim
allogen
blood
critic
import
therapeut
also
inher
riski
biolog
sourc
materi
among
danger
transmiss
wide
rang
pathogen
donor
select
blood
test
reduc
risk
dramat
remain
cornerston
blood
safeti
programm
nevertheless
infecti
unit
still
elud
screen
test
test
error
product
releas
error
probabl
imposs
elimin
largest
current
infecti
risk
involv
pathogen
test
test
demograph
screen
test
inadequ
greatest
fear
concern
emerg
new
transmiss
agent
particularli
one
previous
associ
human
diseas
long
silent
period
infect
other
secondari
spread
highli
lethal
case
hiv
ideal
techniqu
would
provid
addit
safeguard
experi
plasma
fraction
industri
singl
method
like
effect
everi
class
agent
everi
blood
compon
combin
techniqu
remov
inactiv
infecti
agent
probabl
need
technolog
gener
expens
potenti
profoundli
escal
cost
blood
cost
may
partial
offset
elimin
test
marker
howev
potent
techniqu
preserv
blood
function
evid
new
toxic
risk
creat
develop
world
embrac
myth
transfus
like
adopt
almost
regardless
cost
develop
world
blood
donor
premium
eleg
test
method
often
feasibl
good
perfect
pathogen
reduct
method
especi
rel
inexpens
easi
implement
could
save
million
live
